Abstract
Rheumatoid arthritis (RA) is an autoimmune disease represented by chronic inflammation and following structural damage at the articular joints. Progression of the disease causes disability and subsequent early retirement or a care-requiring condition. Although new agents have the potential of complete inhibition of joint damage, there is still a considerable number of patients with progressed joint damage who couldn't receive the benefits of these agents because of the long duration of their disease or uncontrollable disease activity. Thus, a new treatment tool for RA aiming at joint repair is necessary. Mesenchymal stem cells (MSCs) are known to build bone and cartilage, and also have immunosuppressive ability. We have considered MSCs as a new treatment tool of RA, and have reported that MSCs suppress osteoclastogenesis. More recently, we also reported that inflammation induces osteogenesis and suppresses the chondrogenesis of MSCs. An investigation of a new delivery system of MSCs to the target lesion is now ongoing. The data from this investigation suggest that MSCs can be a new application in the treatment of RA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
